{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06443385",
            "orgStudyIdInfo": {
                "id": "AAAV1928"
            },
            "secondaryIdInfos": [
                {
                    "id": "AEARCTR-0013549",
                    "type": "REGISTRY",
                    "domain": "AEA RCT Registry (socialscienceregistry.org)"
                }
            ],
            "organization": {
                "fullName": "Columbia University",
                "class": "OTHER"
            },
            "briefTitle": "E-mails to Nudge Safer and Better-Informed Prescribing of Risky Drugs",
            "officialTitle": "E-mails to Nudge Safer and Better-Informed Prescribing of Risky Drugs",
            "therapeuticArea": [
                "Other"
            ],
            "study": "e-mails-to-nudge-safer-and-better-informed-prescribing-of-risky-drugs"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-17",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-08-17",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-30",
            "studyFirstSubmitQcDate": "2024-06-04",
            "studyFirstPostDateStruct": {
                "date": "2024-06-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Columbia University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "University of Southern California",
                    "class": "OTHER"
                },
                {
                    "name": "Bowdoin College",
                    "class": "OTHER"
                },
                {
                    "name": "Abdul Latif Jameel Poverty Action Lab",
                    "class": "OTHER"
                },
                {
                    "name": "Minnesota Management and Budget",
                    "class": "UNKNOWN"
                },
                {
                    "name": "Minnesota Board of Pharmacy",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will test e-mails to encourage engagement with the Minnesota prescription monitoring program (PMP/PDMP) and will evaluate the effect of these e-mails on PMP/PDMP use and controlled substance prescribing.",
            "detailedDescription": "Drug overdose deaths have skyrocketed in recent years, and many overdoses continue to involve prescribed medications like opioids and stimulants. At the same time, state prescription drug monitoring programs (PDMPs), which help clinicians prescribe these medications safely, remain underused. In Minnesota, 32% of opioid prescriptions are written by clinicians who do not use the PDMP. In many states, including Minnesota, policymakers have limited tools to raise PDMP use even though it is often required under state law. To address this policy dilemma, this study will test e-mails designed to facilitate PDMP use and evaluate their effects on PDMP use and controlled substance prescribing. This study will include a projected 7,126 physician and physician assistant prescribers of opioids and other controlled substances who lack active PDMP accounts, never query the PDMP, or query the PDMP infrequently relative to their prescribing volume. To generate evidence on clinician motivation for responding to encouragement, the study will randomly vary messaging to focus on legal requirements to use the PDMP vs. clinical benefits of the PDMP."
        },
        "conditionsModule": {
            "conditions": [
                "Opioid Prescribing",
                "Prescription Drug Misuse"
            ],
            "keywords": [
                "opioids",
                "prescribing",
                "overprescribing",
                "prescription drug monitoring programs",
                "controlled substances"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Clinicians will be assigned at random to one of three arms: PDMP legal mandate e-mails, PDMP clinical benefit emails, or a control group.",
                "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 7126,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Legal Mandate Messaging",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Behavioral: PDMP Legal Mandate E-mail"
                    ]
                },
                {
                    "label": "Clinical Benefit Messaging",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Behavioral: PDMP Clinical Benefit E-mail"
                    ]
                },
                {
                    "label": "Control",
                    "type": "NO_INTERVENTION"
                }
            ],
            "interventions": [
                {
                    "type": "BEHAVIORAL",
                    "name": "PDMP Legal Mandate E-mail",
                    "description": "E-mails highlighting the state's legal requirements to use the PDMP. There will be one initial email and one follow-up email one month later.",
                    "armGroupLabels": [
                        "Legal Mandate Messaging"
                    ]
                },
                {
                    "type": "BEHAVIORAL",
                    "name": "PDMP Clinical Benefit E-mail",
                    "description": "E-mails highlighting the clinical benefits of having access to the PDMP and checking the PDMP before prescribing opioids. There will be one initial email and one follow-up email one month later.",
                    "armGroupLabels": [
                        "Clinical Benefit Messaging"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Rate of PDMP Engagement",
                    "description": "An indicator for increased PDMP engagement during the 2-month period after the first e-mails were sent. It will indicate whether the level of engagement rose from the baseline level that resulted in the clinician's enrollment into the study. For clinicians who lacked an account, the outcome will indicate whether they created one; for clinicians with an inactive account, the outcome will indicate whether they reactivated it. For those who never searched, it will indicate any search, and for those who rarely searched, it will indicate whether their search rate rose.",
                    "timeFrame": "2 months"
                },
                {
                    "measure": "Volume of Potentially Guideline-discordant Opioid Prescribing",
                    "description": "A composite of several measures of potentially guideline-discordant opioid prescribing. These will include:\n\n1. Opioid co-prescriptions with other opioids\n2. Opioid co-prescriptions with benzodiazepines\n3. Opioid co-prescriptions with gabapentinoids\n4. High daily opioid doses\n5. Long-duration opioid prescriptions to opioid-na\u00efve individuals",
                    "timeFrame": "2 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Minnesota physician or physician assistant\n* Controlled substance prescriber not following state requirements to maintain an active PDMP account, or opioid prescriber not searching the PDMP or infrequently searching the PDMP\n\nExclusion Criteria:\n\n* No e-mail address available",
            "healthyVolunteers": true,
            "sex": "ALL",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Adam Sacarny, PhD",
                    "role": "CONTACT",
                    "phone": "914-715-0217",
                    "email": "ajs2102@cumc.columbia.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Adam Sacarny, PhD",
                    "affiliation": "Columbia University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Mireille Jacobson, PhD",
                    "affiliation": "University of Southern California",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Tatyana Avilova, PhD",
                    "affiliation": "Bowdoin College",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Minnesota Board of Pharmacy",
                    "city": "Minneapolis",
                    "state": "Minnesota",
                    "zip": "55414",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Brock Reed, PharmD",
                            "role": "CONTACT",
                            "email": "Brock.Reed@state.mn.us"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.97997,
                        "lon": -93.26384
                    }
                },
                {
                    "facility": "Minnesota Management and Budget",
                    "city": "Saint Paul",
                    "state": "Minnesota",
                    "zip": "55155",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.94441,
                        "lon": -93.09327
                    }
                },
                {
                    "facility": "Columbia University Irving Medical Center",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Adam Sacarny, PhD",
                            "role": "CONTACT",
                            "phone": "914-715-0217",
                            "email": "ajs2102@cumc.columbia.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000076064",
                    "term": "Drug Misuse"
                },
                {
                    "id": "D000063487",
                    "term": "Prescription Drug Misuse"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1557",
                    "name": "Drug Misuse",
                    "asFound": "Drug Misuse",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30133",
                    "name": "Prescription Drug Misuse",
                    "asFound": "Prescription Drug Misuse",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000033110",
                    "term": "RV 538"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000962",
                    "term": "Antimalarials"
                },
                {
                    "id": "D000000981",
                    "term": "Antiprotozoal Agents"
                },
                {
                    "id": "D000000977",
                    "term": "Antiparasitic Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4033",
                    "name": "Analgesics, Opioid",
                    "relevance": "LOW"
                },
                {
                    "id": "M216702",
                    "name": "RV 538",
                    "asFound": "Airbag",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4280",
                    "name": "Antimalarials",
                    "relevance": "LOW"
                },
                {
                    "id": "M4298",
                    "name": "Antiprotozoal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4294",
                    "name": "Antiparasitic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}